Putnam Investments’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Putnam Investments’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,845	Closed	-$2.67M	–	1002
2018 Q4	$2.67M	Hold	5,845	–	–	0.01%	586
2018 Q3	$5.31M	Sell	5,845 -1,865	-24%	-$1.23M	0.01%	551
2018 Q2	$4.52M	Buy	7,710 +1,842	+31%	+$1.2M	0.01%	556
2018 Q1	$3.82M	Buy	5,868 +5,556	+1,781%	+$4.17M	0.01%	565
2017 Q4	$114K	Hold	312	–	–	﹤0.01%	1069
2017 Q3	$96K	Sell	312 -1	-0.3%	-$380	﹤0.01%	1098
2017 Q2	$150K	Sell	313 -2,749	-90%	-$2.08M	﹤0.01%	1090
2017 Q1	$3.81M	Sell	3,062 -111	-3%	-$53.4K	0.01%	704
2016 Q4	$1.28M	Hold	3,173	–	–	﹤0.01%	948
2016 Q3	$1.32M	Sell	3,173 -15	-0.5%	-$6.71K	﹤0.01%	953
2016 Q2	$1.49M	Buy	3,188 +1	+0%	+$508	﹤0.01%	1014
2016 Q1	$1.65M	Sell	3,187 -11	-0.3%	-$6.15K	﹤0.01%	995
2015 Q4	$2.51M	Hold	3,198	–	–	0.01%	914
2015 Q3	$4.39M	Buy	3,198 +631	+25%	+$974K	0.01%	714
2015 Q2	$5.15M	Buy	+2,567	New	+$6.55M	0.01%	716

Other funds holding HTGM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Putnam Investments's HTGM Position: Q1 2019 in Review

Putnam Investments sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q1 2019, closing a stake of 5,845 shares — an estimated $2.67M sold.

Putnam Investments first reported a position in HTGM in Q2 2015 and held it in 15 quarters. The position peaked at $5.31M in Q3 2018. 39 funds tracked by Wall St. Rank hold HTGM as of Q1 2019.

Putnam Investments reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Putnam Investments sold 5,845 HTG Molecular Diagnostics, Inc. Common Stock shares in Q1 2019, an estimated $2.67M.
Putnam Investments first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 15 quarters.
Putnam Investments's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $5.31M in Q3 2018.
39 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q1 2019.

Based on Putnam Investments's 13F filing for Q1 2019, filed 15 May 2019.